EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

IUPHAR review: From gut to brain: The role of gut dysbiosis, bacterial amyloids, and metabolic disease in Alzheimer’s disease

Saadet Inan, R Paul Wilson, Çagla Tükel

Pharmacological Research · 2025-05 · 215 · 107693

DOI: 10.1016/j.phrs.2025.107693 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmacological Research, 2025-05. Verfasst von Saadet Inan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. Electronic address: saadet.inan@temple.…. Hauptthemen laut MEDLINE: Alzheimer Disease, Dysbiosis, Gastrointestinal Microbiome, Brain. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gut microbial dysbiosis, or altered gut microbial communities, in Alzheimer's Disease suggests a pathogenic role for gut inflammation and microbial products in shaping a neuroinflammatory environment. Similarly, metabolic diseases, such as obesity and diabetes, are also associated with an increased risk of Alzheimer's Disease. As the metabolic landscape shifts during gut inflammation, and gut inflammation in turn impacts metabolic processes, we explore how these interconnected pathways may contribute to the progression of Alzheimer's Disease. Additionally, we discuss the role of bacterial amyloids produced by gut microbes, which may exacerbate amyloid aggregation in the brain and contribute to neurodegenerative processes. Furthermore, we highlight potential therapeutic strategies aimed at reducing gut inflammation, improving metabolic health, and decreasing amyloid content as a means to mitigate Alzheimer's Disease progression. These approaches, targeting the gut-brain-metabolic axis, could offer promising avenues for delaying or preventing cognitive decline in affected individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseDysbiosisGastrointestinal MicrobiomeBrainAmyloidMetabolic DiseasesHumansAnimalsBrain-Gut Axis

Stichwörter der Autor:innen

Alzheimer's diseaseAmyloidBiofilmCurliDysbiosisMetabolic disease

Substanzen

Amyloid

Autor:innen und Institutionen

  • Center for Substance Abuse Research, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. Electronic address: saadet.inan@temple.edu.
  • Center for Microbiology and Immunology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.
  • Center for Microbiology and Immunology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA. Electronic address: cagla.tukel@temple.edu.

Förderung

  • NIAID NIH HHS
  • Intramural Research Program, National Institute on Drug Abuse
  • National Institutes of Health
  • National Institute of Allergy and Infectious Diseases Division of Intramural Research

Zitieren

APA

Inan, S., Wilson, R. P., & Tükel, Ç. (2025). IUPHAR review: From gut to brain: The role of gut dysbiosis, bacterial amyloids, and metabolic disease in Alzheimer’s disease. Pharmacological Research, 215, 107693. https://doi.org/10.1016/j.phrs.2025.107693

Vancouver

Inan S, Wilson RP, Tükel Ç. IUPHAR review: From gut to brain: The role of gut dysbiosis, bacterial amyloids, and metabolic disease in Alzheimer’s disease. Pharmacological Research. 2025;215:107693. doi:10.1016/j.phrs.2025.107693

BibTeX
@article{Inan2025,
  author = {Inan, Saadet and Wilson, R Paul and Tükel, Çagla},
  title = {IUPHAR review: From gut to brain: The role of gut dysbiosis, bacterial amyloids, and metabolic disease in Alzheimer’s disease},
  journal = {Pharmacological Research},
  year = {2025},
  volume = {215},
  pages = {107693},
  doi = {10.1016/j.phrs.2025.107693}
}
Kostenlos starten →